Selective serotonin reuptake inhibitors and the risk for suicidality in adolescents: An update

Lucas Giner, C. Matthew Nichols, Gil Zalsman, Maria A. Oquendo

Research output: Contribution to journalReview articlepeer-review

Abstract

The controversy regarding Selective Serotonin Reuptake Inhibitors (SSRIs) and suicidality dates back to the early 1990s. The first agent reported to be associated with suicidality was fluoxetine. In 2003, the British Medicines and Healthcare Products Regulatory Agency (MHRA) warned about possible risk of suicidality in children and adolescents treated with paroxetine for Major Depressive Disorder (MDD). This warning was soon extended to all the SSRIs as well as venlafaxine and mirtazapine. Similarly, the United States Food and Drug Administration (FDA) issued a "black box warning" on these medications in 2004. We address the debate concerning this warning and its clinical implications and review the latest contributions to the literature.

Original languageEnglish
Pages (from-to)211-220
Number of pages10
JournalInternational Journal of Adolescent Medicine and Health
Volume17
Issue number3
DOIs
StatePublished - 2005

Keywords

  • Adolescents
  • FDA
  • Fluoxetine
  • Paroxetine
  • Safety
  • SSRI
  • Suicidality
  • Suicide

Fingerprint

Dive into the research topics of 'Selective serotonin reuptake inhibitors and the risk for suicidality in adolescents: An update'. Together they form a unique fingerprint.

Cite this